Report Of The Month - Best Annual Reports - e.com ReportWatch

ReportWatch Best Annual Reports

You are here:
ReportWatch
> Best Annual Reports
> Report of the month
> Novo Nordisk

Report of the month

October 2010

Download as PDF
Novo Nordisk Bagsvaerd, Denmark Report Facts Company name: Novo Nordisk A/S Fiscal year end: December 31, 2009 Report title: Creating value through innovation Chairman of the Board: Sten Scheibye President and CEO: Lars Rebien Sörensen Number of books: One + Online supplements Report length: 108 pages Auditors: PrcewaterhouseCoopers Design: ADtomic Communications, Team2Graphics E-mail: mike@novonordisk.com; klda@novonordisk.com	Report Rating 3.5/5 (Rating scale below) Profile-Products (Excerpts, as from the report) For more than 85 years, Novo Nordisk has combined drug discovery with technology to turn science into solutions for people with diabetes, ... with haemophilia, ... with growth hormone deficiency... Our commitment to research is reflected in our full portfolio of insulin products and the many new treatment options in our pipeline... decisions about our operations are driven by the Triple Bottom Line... (Annual Report) (Italics are own company’s words) Key Figures Sales total: DKK 51,078 million Operating income: DKK 14,933 million Net profit: DKK 10,768 million Earnings per share: DKK 17.82 Dividend per share: DKK 7.50 Return on invested capital: 47.3% Operating margin: 29.2% Number of employees: 29,329 (Source: 2009 figures sourced from the annual report) Competitors and Peers Lundbeck Novozymes Eli Lilly GlaxoSmithKline AstraZeneca Pfizer Novartis Sanofi-Aventis Abbott Merck Takeda ...

Triple A > A trailblazer in “triple bottom line” reporting -financial, social, environmental- that sustains an integrated approach (see Our impact on society in Selected Page below), from Performance highlights (which include non-financial indicators) to working methods and to an entire section of non-financial statements and notes. An approach increasingly emulated, but not that often matched.

Double A > User-friendly formatted online report, built around topics and issues, departing from a linear in-print structure (e.g. through multiple entries and menu bars) and adding extra information to the more concise book (only a bit more than 100 pages long). > Pipeline information available quickly and plainly written, also in a user-friendly web version. > 2009 performance against financial targets charts and reviews four objectives over the last five years. > Transparency about shareholders and fairly developed share information. > Comprehensive historical performance data, for economic, financial and non-financial measures. > How we work with business ethics (p 34).

Simple A > Informative review of business areas, based on issues. Lacks an overview of year events and reading facilitators (both online and in print). > Governance and remuneration reports are up. > Notes to statements unevenly commented.

B Sides > Liquidity analysis is far from elaborate. > Sure there are a few illustrations, sketches and charts, but both the web and the printed reports are not that read-appealing and much animated.

How does the company report in key areas? What are the main report pluses and minuses? The Report Scan gives an overview of strengths and weaknesses, and scores each item. Contact e.com@reportwatch.net

Selected Page (p30 of Novo Nordisk Annual Report 2009)	Rating Scale 5 First-Rate 4.5 Excellent 4 Very good 3.5 Sound 3 Average 2.5 Uneven 2 Common 1.5 Substandard 1 Poor 0.5 Uncompetitive The rating is based on ReportWatch internal desk research and does not take into account the independent Rating Panel’s judgment.